Tonix Pharmaceuticals Holding Corp. recently highlighted its current clinical and commercial activities in a presentation. The company is focused on developing therapeutics for conditions involving pain, neurology, psychiatry, and addiction, as well as areas like immunology, infectious diseases, and rare diseases. Their key clinical program, TNX-102 SL, is being developed for fibromyalgia, with an FDA decision on marketing authorization expected by August 15, 2025. The program has been granted FDA Fast Track Designation, and potential product launch is anticipated for 2025. Additionally, Tonix is advancing TNX-1500, an anti-CD40L monoclonal antibody, for organ transplant rejection and autoimmune conditions, having completed a Phase 1 study. The company is also marketing products like Zembrace® and Tosymra® for acute migraine treatment. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。